Published in Ann Vasc Dis on January 01, 2013
Is the peripheral arterial disease in low risk type 2 diabetic patients influenced by body mass index, lipidemic control, and statins? J Pharmacol Pharmacother (2016) 0.76
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 16.32
Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA (2001) 13.65
Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation (2004) 7.30
Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA (2009) 5.66
Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg (2000) 5.50
Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation (1993) 4.75
Peripheral arterial disease in people with diabetes. Diabetes Care (2003) 4.36
Medical treatment of peripheral arterial disease and claudication. N Engl J Med (2001) 3.92
Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA (1997) 3.87
High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis (2004) 3.55
Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care (2004) 3.46
Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol (1998) 3.37
Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation (2009) 3.28
Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care (1999) 3.06
The prevalence of peripheral arterial disease in a defined population. Circulation (1985) 2.88
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation (1998) 2.83
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2011) 2.71
Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab (2011) 2.42
Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med (2003) 2.41
Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J (2002) 2.38
Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation (1997) 2.29
Exercise training for claudication. N Engl J Med (2002) 2.26
Treatment for diabetic foot ulcers. Lancet (2005) 1.91
Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care (2001) 1.82
Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation (1995) 1.74
Prevalence and management of diabetes and associated risk factors by regions of Thailand: Third National Health Examination Survey 2004. Diabetes Care (2007) 1.71
Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J Intern Med (2002) 1.29
Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing. Vasc Med (1999) 1.21
Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care (2003) 1.17
Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg (2006) 1.11
Medical therapy in peripheral artery disease. Circulation (2012) 1.08
Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs (2002) 1.04
Multi-country study on the prevalence and clinical features of peripheral arterial disease in Asian type 2 diabetes patients at high risk of atherosclerosis. Diabetes Res Clin Pract (2006) 1.04
The incidence of type 2 diabetes mellitus in the Philippines: a 9-year cohort study. Diabetes Res Clin Pract (2009) 1.00
A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med (2010) 0.99
Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation (2000) 0.92
Peripheral vascular disease in diabetes mellitus and its relation to cardiovascular risk factors: screening with the doppler ultrasonic technique. Diabetes Care (1980) 0.91
Effects of beraprost sodium (Dorner) in patients with diabetes mellitus complicated by chronic arterial obstruction. Angiology (2002) 0.90
Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1). Cardiovasc Res (2001) 0.89
High prevalence of peripheral arterial disease diagnosed by low ankle-brachial index in Japanese patients with diabetes: the Kyushu Prevention Study for Atherosclerosis. Diabetes Res Clin Pract (2008) 0.88
Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg (2005) 0.88
Intermittent claudication. The natural history. Surg Clin North Am (1995) 0.86
Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease. The Edinburgh Artery Study. Diabetes Care (1999) 0.85
Thailand diabetes registry project: prevalence of vascular complications in long-standing type 2 diabetes. J Med Assoc Thai (2006) 0.84
Prevalence and risk factors of peripheral arterial disease in a selected Thai population. Angiology (2007) 0.81
Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus. Vasc Health Risk Manag (2005) 0.80
Beraprost sodium, an orally active prostaglandin I(2) analog, improves renal anemia in hemodialysis patients with peripheral arterial disease. Ther Apher Dial (2010) 0.78
Lower extremity arterial reconstruction in patients with diabetes mellitus. Diabet Med (1996) 0.76
Antithrombotic therapy in peripheral arterial occlusive disease. Chest (1995) 0.76